Launch Date
11/18/2020
Credit Amount
0.00 Expired
Credit Expires
11/08/2021
There are many factors impeding the accurate diagnosis of bipolar disorder, including that it is difficult to differentiate bipolar I disorder (BD-I) and bipolar II disorder (BD-II) from unipolar depression, particularly in those with no clear history of mania or hypomania or who present during a depressive episode. Additionally, the prevalence of depressive symptoms is higher than that of hypomanic or manic symptoms during the course of BD-I or BD-II, with the proportion of time ill accounted for by depression being 70% in BD-I and 80% in BD-II. Therefore, it is imperative that physicians note diagnostic criteria and diagnostic aids and utilize rapid assessment tools such as the Mood Disorders Questionnaire (MDQ), Composite International Diagnostic Interview (CIDI), and the Rapid Mood Screener (RMS) when assessing mood disorders.
In this CME Outfitters BriefCase, expert faculty will present a patient case that shows how to detect BD-I, differentiate BD-I and BD-II and other mimickers, and use evidence-based screening tools to improve detection of BD-I in order to promote early administration of effective care.
At the end of this CME/CE activity, participants should be able to implement diagnostic criteria and evidence-based tools to improve detection of bipolar I disorder for early administration of effective care.
The following learning objectives pertain only to those requesting CNE or CPE credit: Assess diagnostic criteria and evidence-based tools to improve the detection of bipolar I disorder for early administration of effective care.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McIntyre reports that he receives grants/research support from The Canadian Institutes of Health Research (CIHR); Global Alliance for Chronic Diseases (GACD); National Natural Research Foundation of China; and Stanley Medical Research Institute. He is a consultant/on the speakers bureau for Allergan; Intra-Cellular Therapies Inc.; Janssen Pharmaceutical, Inc.; Lundbeck Canada Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka Canada Pharmaceutical Inc.; Pfizer Inc.; Purdue Pharma Canada; Sunovion Pharmaceuticals Canada Inc.; and Takeda Pharmaceutical Company Limited.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
BC-031-111820-41